Latest News-KAZIA THERAPEUTICS LIMITED. Mediaroom_Page

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...

2021-11-16 00:00 1723

PNOC Study in Childhood Brain Cancer Enrols First Patient

SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...

2021-11-11 21:00 2526

Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an onco...

2021-09-11 00:30 19955

Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs

SYDNEY, June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...

2021-06-30 22:00 30020

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncol...

2021-06-15 22:00 10973

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncolo...

2021-06-07 20:00 6499

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an onco...

2021-04-19 17:54 3295

Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company

SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an onco...

2021-03-29 17:43 3383

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2021-03-02 07:00 4097

Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG

SYDNEY, Dec. 10, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-12-10 12:51 6086

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austra...

2020-12-09 07:49 3196

Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

SYDNEY, Nov. 18, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-11-18 07:39 2948

Kazia Executes Agreement To Commence GBM Agile Pivotal Study

SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-10-16 07:30 12385

Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...

2020-09-22 09:21 7594

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-08-24 09:14 6344

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...

2020-08-20 08:35 8509

US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austra...

2020-08-07 08:30 13866

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

SYDNEY, June 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...

2020-06-22 12:39 3975

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

SYDNEY, June 1, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austra...

2020-06-01 08:45 4917

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

SYDNEY, April 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-04-07 20:00 3698